Mikhail Blagosklonny initiating Breakthrough in the field of Cancer and Aging

Traces of hope can be seen flickering at the far-edge of the fight against cancer as several oncologists try to find a remedy to the deadliest disease of our time. Medical scientists who specialize in the field of cancer are working day and night in highly equipped laboratories and other medical facilities to come up with discoveries and possible treatment methodologies to curb this disease. Among the notable names who have dedicated their career to this course is Mikhail Blagosklonny.

Mikhail Blagosklonny is currently a professor of oncology at a cancer institute know as Roswell Park. He received his Master’s Degree in internal medicine and later a PhD in experimental medicine and cardiology from the Pavlov State Medical University of St. Petersburg. His main area of specialization is anti-aging and oncology. Blagosklonny boasts of a successful career that has seen him lecturer in various prestigious academic institutions and head of various health-science related institutions. He was appointed at the New York Medical College that is found in Valhalla for the role of associate professor of medicine in the year 2002. With an impeccable performance record at the New York Medical College, Blagosklonny was appointed as a senior scientist at the Ordway Research Institute in Albany, New York, after which he was appointed professor of oncology at Roswell Park Cancer Center. Read more about Mikhail at LinkedIn.com

He also doubles as an editor; mostly editing for cancer-related research journals. He is the editor-in-chief of Aging, a monthly peer-reviewed open access medical journal that covers research on gerontology, molecular mechanics of aging and senescence. Mikhail Blagosklonny is also the editor-in-chief of the cell cycle and Oncotarget. He is associate editor of Cancer Biology & Therapy Journal and a member of the Editorial Board of Cell Death & Differentiation journal. Most of these journals focus on research on oncology cell cycle, signal transduction as well as tumor suppressors.

Blagosklonny’s recent hypothesis on the role of Target of Rapamycin (TOR) signaling in cancer and aging received wide acclamation as it suggests a leeway to cure for the two diseases. He has gone ahead to suggest the use of Rapamycin, which is a popular cancer drug for treatment of ageing. Follow Mikhail on Loop